Thanks to its Covid-19 vaccine, Pfizer can expect historic profit in 2021

The vaccine against Covid-19 will allow the American pharmaceutical group Pfizer to reach an estimated turnover of 60 billion dollars.

ASSOCIATED PRESS - Mark Lennihan

Text by: RFI Follow

2 min

The American pharmaceutical group Pfizer estimates that sales of its anti-Covid vaccine, developed in partnership with BioNTech, will reach around $ 15 billion in 2021. A colossal sum that could increase if the laboratory signs additional contracts.

Publicity

Read more

It is one of the biggest successes in the history of pharmacy.

In the fourth quarter of 2020 alone, Pfizer sold the Covid-19 vaccine for $ 154 million.

The American group, in partnership with the German BioNTech, is one of the first to have developed its vaccine.

After a week of hesitation in January and

delays in delivery

to certain European countries, the group has committed to deliver 200 million doses to the United States by the end of May and 300 million in total to the European Union.

Revenge

The Swiss Novartis and French Sanofi laboratories are now helping with manufacturing.

Thus Pfizer and BioNTech hope to be able to produce a total of two billion doses of their anti-Covid vaccine by the end of the year.

A revenge for the American group whose net profit had fallen by 41% in 2020. The technological prowess of this vaccine based on the messenger RNA method will allow Pfizer to reach an estimated turnover of 60 billion dollars .

This is 20 billion more than last year.

► 

Read also: Covid-19: the sixth dose of the Pfizer vaccine creates controversy

Newsletter

Receive all the international news directly in your mailbox

I subscribe

Follow all the international news by downloading the RFI application

google-play-badge_FR

  • Coronavirus

  • Vaccines

  • United States

  • European Union

On the same subject

Israel obtained vaccine stock in exchange for medical data from Pfizer

The controversy over Pfizer vaccine doses continues, this time in Sweden

Covid-19: the sixth dose of the Pfizer vaccine creates controversy